Dietary carbohydrates and fatty liver disease: De novo lipogenesis

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 21, Issue 4, 2018, Pages 277-282

  Chiu, Sally ^a,b   Mulligan, Kathleen ^a,c,d   Schwarz, Jean Marc ^a,c,d  

^a Touro University California   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

carbohydrate; fructose; lipogenesis; nonalcoholic fatty liver disease; sugar

Indexed keywords

FRUCTOSE;

CARBOHYDRATE DIET; DE NOVO LIPOGENESIS; HUMAN; LIPID LIVER LEVEL; LIPOGENESIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; DIET; DRUG EFFECT; ENERGY METABOLISM; LIVER; METABOLISM; SUGAR INTAKE;

DIET; DIETARY CARBOHYDRATES; DIETARY SUGARS; ENERGY METABOLISM; FRUCTOSE; HUMANS; LIPOGENESIS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85048273375     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000469     Document Type: Review

References (43)

1. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data. Am J Gastroenterol 2017; 112:581-587.
2. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat RevGastroenterol Hepatol 2018; 15:11-20.
3. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73-84.
4. Goffredo M, Mass K, Parks EJ, et al. Role of gut microbiota and short chain fatty acids in modulating energy harvest and fat partitioning in youth. J Clin Endocrinol Metab 2016; 101:4367-4376.
5. Puri P, Sanyal AJ. The intestinal microbiome in nonalcoholic fatty liver disease. Clin Liver Dis 2018; 22:121-132.
6. Jones GM, Mulligan K, Schwarz JM. Dietary carbohydrate restriction in the management of NAFLD and metabolic syndrome. In: Bergeron N, Siri-Tarino PW, Bray GA, Krauss RM, editors. Nutrition and cardiometabolic health. Boca Raton, FL: CRC Press; 2017. pp. 275-296.
7. Schwarz JM, Clearfield M, Mulligan K. Conversion of sugar to fat: is hepatic de novo lipogenesis leading to metabolic syndrome and associated chronic diseases? J Am Osteopath Assoc 2017; 117:520-527.
8. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146:726-735.
9. Umpleby AM, Shojaee-Moradie F, Fielding B, et al. Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets. Clin Sci 2017; 131:2561-2573.
10. Cazanave S, Podtelezhnikov A, Jensen K, et al. The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci Rep 2017; 7:17193.
11. Zhang D, Tong X, VanDommelen K, et al. Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. J Clin Invest 2017; 127:2855-2867.
12. Cui XB, Luan JN, Chen SY. RGC-32 deficiency protects against hepatic steatosis by reducing lipogenesis. J Biol Chem 2015; 290:20387-20395.
13. Patankar JV, Wong CK, Morampudi V, et al. Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. Am J Physiol Endocrinol Metab 2017. [Epub ahead of print]
14. Softic S, Gupta MK, Wang GX, et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest 2017; 127:4059-4074. The mouse study parsed out the distinct mechanisms underlying fructose-induced vs. glucose-induced hepatic steatosis. Through a series of studies, authors demonstrated that although high intakes of both sugars increase liver fat content, fructose does so by increasing de novo lipogenesis (DNL), whereas glucose increases triglyceride synthesis. Furthermore, these differences were observed on the background of a high saturated fat, and not chow diet, indicating the importance of other dietary factors in determining the extent of sugar-induced metabolic effects.
15. Lombardi R, Onali S, Thorburn D, et al. Pharmacological interventions for nonalcohol related fatty liver disease (NAFLD): an attempted network metaanalysis. Cochrane Database Syst Rev 2017; 3:CD011640.
16. Stiede K, Miao W, Blanchette HS, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology 2017; 66:324-334.
17. Kim CW, Addy C, Kusunoki J, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab 2017; 26:394-406.e6.
18. Woods A, Williams JR, Muckett PJ, et al. Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep 2017; 18:3043-3051. The study in mice with chronic liver-specific activation of AMP activated protein kinase gene (AMPK) provides evidence for AMPK as an attractive pharmaceutical target for nonalcoholic fatty liver disease. Activation of AMPK in the liver dramatically reduced liver fat in mice consuming a high-fructose diet, with no other detectable metabolic effects.
19. Huard K, Ahn K, Amor P, et al. Discovery of fragment-derived small molecules for in vivo inhibition of ketohexokinase (KHK). J Med Chem 2017; 60: 7835-7849.
20. Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol 2017; 23:1-12.
21. Lauridsen BK, Stender S, Kristensen TS, et al. Liver fat content, nonalcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279,013 individuals. Eur Heart J 2018; 39:385-393.
22. Mancina RM, Matikainen N, Maglio C, et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J Clin Endocrinol Metab 2015; 100:E821-E825.
23. Santoro N, Caprio S, Pierpont B, et al. Hepatic de novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene. J Clin Endocrinol Metab 2015; 100:E1125-E1132.
24. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328-357.
25. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013; 57:2525-2531.
26. World Health Organization. Guidelines: Sugar Intake for Adults and Children. Geneva, Switzerland: World Health Organization; 2015.
27. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015-2020 Dietary Guidelines for Americans. 8th Edition. December 2015. Available at https://health.gov/dietaryguidelines/2015/ guidelines/.
28. Bawden S, Stephenson M, Falcone Y, et al. Increased liver fat and glycogen stores after consumption of high versus low glycaemic index food: a randomized crossover study. Diabetes Obes Metab 2017; 19:70-77.
29. Misciagna G, Del Pilar Diaz M, Caramia DV, et al. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017; 21:404-412.
30. Felix DR, Costenaro F, Gottschall CB, Coral GP. Nonalcoholic fatty liver disease (NAFLD) in obese children-effect of refined carbohydrates in diet. BMC Pediatr 2016; 16:187.
31. Errazuriz I, Dube S, Slama M, et al. Randomized controlled trial of a MUFA or fiber-rich diet on hepatic fat in prediabetes. J Clin Endocrinol Metab 2017; 102:1765-1774.
32. Mosca A, Nobili V, De Vito R, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 2017; 66:1031-1036.
33. Chung M, Ma J, Patel K, et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014; 100:833-849.
34. Schwarz JM, Noworolski SM, Wen MJ, et al. Effect of a high-fructose weightmaintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab 2015; 100:2434-2442.
35. Taskinen MR, Soderlund S, Bogl LH, et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J Intern Med 2017; 282:187-201. The longer term 12-week study on the metabolic effects of increased fructose intake was conducted with more moderate fructose supplementation (75 g/day) in a relatively large sample size (n71). The study used an oral fat tolerance test to demonstrate that dietary fructose can elicit more chronic effects on DNL.
36. Lustig RH, Mulligan K, Noworolski SM, et al. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity 2016; 24:453-460.
37. Schwarz JM, Noworolski SM, Erkin-Cakmak A, et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 2017; 153:743-752. In this detailed and carefully conducted study in 41 obese children, fructose restriction within an energy balanced diet was shown to reduce DNL and liver fat as well as improve insulin kinetics in as little as 9 days, providing strong evidence for the benefit of reducing fructose intake.
38. Ibarra-Reynoso LDR, Lopez-Lemus HL,Garay-Sevilla ME, Malacara JM. Effect of restriction of foods with high fructose corn syrup content on metabolic indices and fatty liver in obese children. Obes Facts 2017; 10:332-340.
39. Campos V, Despland C, Brandejsky V, et al. Sugar-and artificially sweetened beverages and intrahepatic fat: a randomized controlled trial. Obesity 2015; 23:2335-2339.
40. Jensen MD. Fate of fatty acids at rest and during exercise: regulatory mechanisms. Acta Physiol Scand 2003; 178:385-390.
41. Magkos F, Sidossis LS. Measuring very low density lipoprotein-triglyceride kinetics in man in vivo: how different the various methods really are. Curr Opin Clin Nutr Metab Care 2004; 7:547-555.
42. Quintard H, Fontaine E, Ichai C. Energy metabolism: from the organ to the cell. In: Ichai C, Quintard H, Orban JC, editors. Metabolic disorders and critically ill patients. Cham: Springer; 2018. pp. 441-451.
43. Pierce AA, Duwaerts CC, Soon RK, et al. Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. J Nutr Biochem 2016; 29:12-20.